BIOPAT, Biopatologia Molecular, Grup Assistencia, Avda. Diagonal 660, Planta -1, 08034 Barcelona, Spain.
Virchows Arch. 2013 Jun;462(6):639-44. doi: 10.1007/s00428-013-1415-3. Epub 2013 May 24.
ERG gene rearrangement has been identified as a highly specific alteration that is present in 40-50 % of prostate carcinomas. The standardization of an immunohistochemical assay with a novel anti-ERG antibody recently described would have significant diagnostic value. The aims of this study were to identify the incidence of this rearrangement in a Spanish population and to test the specificity of immunohistochemical ERG evaluation for prostate carcinomas. Three prostate tissue microarrays were constructed using radical prostatectomy specimens and related to grade, local invasion, and regional invasion. In addition to samples from malignant cases (160), specimens of prostatic hyperplasia (26) and high-grade prostatic intraepithelial neoplasia (10) were included. Tissue microarrays of 270 samples from most common malignant tumors (breast, colon, lung, and bladder) were also tested. All were analyzed by immunohistochemistry. Seventy-five out of 154 evaluable cases (49 %) of prostate carcinoma showed ERG expression; 52/75 showed strong staining. No ERG expression was observed in any of the high-grade prostatic intraepithelial neoplasia. ERG expression was independent of Gleason score (p = 0.160), extent of invasion (p = 0.517), and regional lymph node involvement (p = 0.816). No ERG expression was found in any other type of tumor, with the exception of one bladder cancer sample that showed focal and weak expression. The frequency of ERG detected in our study correlated with the results published for other Caucasian populations. Strong ERG protein expression was exclusively detected in prostate carcinomas, corroborating the specificity of ERG rearrangements for these tumors. Thus, detecting ERG using immunohistochemistry may be useful in routine practice in pathology departments.
ERG 基因重排已被确定为高度特异性改变，存在于 40-50%的前列腺癌中。最近描述的一种新型抗-ERG 抗体的免疫组织化学检测方法的标准化将具有重要的诊断价值。本研究的目的是确定这种重排在西班牙人群中的发生率，并测试免疫组织化学 ERG 评估前列腺癌的特异性。使用根治性前列腺切除术标本构建了三个前列腺组织微阵列，并与分级、局部浸润和区域浸润相关。除了恶性病例（160 例）的样本外，还包括前列腺增生（26 例）和高级别前列腺上皮内瘤变（10 例）的样本。还测试了 270 例常见恶性肿瘤（乳腺、结肠、肺和膀胱）的组织微阵列样本。所有样本均通过免疫组织化学进行分析。在 154 例可评估的前列腺癌病例中，有 75 例（49%）显示 ERG 表达；52/75 例显示强染色。任何高级别前列腺上皮内瘤变均未观察到 ERG 表达。ERG 表达与 Gleason 评分（p=0.160）、浸润程度（p=0.517）和区域淋巴结受累（p=0.816）无关。除了一个膀胱癌样本显示局灶性和弱阳性表达外，其他类型的肿瘤均未检测到 ERG 表达。在我们的研究中检测到的 ERG 频率与其他白种人群发表的结果相关。强烈的 ERG 蛋白表达仅在前列腺癌中检测到，证实了 ERG 重排在这些肿瘤中的特异性。因此，使用免疫组织化学检测 ERG 可能在病理科的常规实践中有用。
